News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Bioheart, Inc. Provides Update: Clinical Studies Strategy and Progress
January 11, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SUNRISE, Fla., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH TOZARO
The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges
August 11, 2025
·
8 min read
·
BioSpace Insights
Obesity
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
August 7, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market
August 6, 2025
·
2 min read
·
Annalee Armstrong
Venture capital
Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future
August 6, 2025
·
5 min read
·
Heather McKenzie
